Oligo-conjugates: an Answer to a Delivery Conundrum?
Oligonucleotide-based therapies have a significant presence within the pharmaceutical industry. According to Hanson Wade’s Beacon database, there have been 15 oligonucleotide-based drugs approved for the market, the first coming way back in 1998 with fomivirsen and the latest, vutrisiran, last year. Despite this apparent success, there remains a persistent issue within the space concerning the delivery of these molecules to target tissues.
Get in touch
We speak to hundreds of biopharmaceutical experts from industry and academia every day. We would love for you to be one of them. Contact us to discover how our events can accelerate your drug development.
Standard Form - Process Development & Manufacturing
"*" indicates required fields